Shan Wang,
Leland T. Edwards Professor in the School of Engineering,
Stanford University
Dr. Wang is the Leland T. Edwards Professor in the School of Engineering, Stanford University. He is a Professor and Associate Chair of Materials Science & Engineering and jointly a Professor of Electrical Engineering, and by courtesy, a Professor of Radiology (Stanford School of Medicine). He directs the Center for Magnetic Nanotechnology, and is a co-Principal Investigator of the Center for Cancer Nanotechnology Excellence for Translational Diagnostics (CCNE-TD) at Stanford University. He has over 270 publications, and holds 59 issued or pending patents in the areas of magnetic nanotechnology and information storage, biosensors, spintronics, and power management. He was named an inaugural Fred Terman Fellow, and he was elected a Fellow of the Institute of Electrical and Electronics Engineers (IEEE) and a Fellow of American Physical Society (APS) for his seminal contributions to magnetic materials and nanosensors. His team won the Grand Challenge Exploration Award from Gates Foundation (2010), the XCHALLENGE Distinguished Award (2014), and the Bold Epic Innovator Award from the XPRIZE Foundation (2017). He cofounded three high-tech startups in Silicon Valley, including MagArray, Inc. and Flux Biosciences, Inc. Dr. Wang obtained his PhD in Electrical and Computer Engineering from Carnegie Mellon University in 1993, MS in Physics from Iowa State University in 1988, and BS in Physics from the University of Science and Technology of China in 1986.
Nanodiagnostic Tool for Comprehensive Assessment of Cancer in Blood
Wednesday, 27 March 2019 at 17:30
Add to Calendar ▼2019-03-27 17:30:002019-03-27 18:30:00Europe/LondonNanodiagnostic Tool for Comprehensive Assessment of Cancer in BloodLiquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Blood borne biomarkers, such as secreted proteins, circulating tumor DNA
(ctDNA) and circulating tumor cell (CTC), have garnered much attention
as minimally invasive cancer biomarkers for the “liquid biopsy” of
tumors over the past decade. In this talk, we will describe three
magnetic-nanoparticle-based diagnostic tools that have been used to
assess cancer in peripheral blood successfully: 1) Stanford spin-off
MagArray Inc. has launched REVEAL, a cancer-specific blood test that may
aid clinicians in characterizing indeterminate pulmonary nodules
(4-30mm) in current smokers aged 25-85. The REVEAL Score is calculated
using an algorithm based on the measurement of 3 clinical factors and 3
blood proteins associated with the presence of lung cancer. The assay is
optimized to rule out lung cancer with a negative predictive value
(NPV) of = 95%. 2) We have developed sequence-specific capture of
hypermethylated or mutated genes of interest from cfDNA for early
detection of NSCLC and colorectal cancer (CRC). With downstream analysis
of PCR products on giant magnetoresistive (GMR) biosensors and
high-resolution melt analysis for a highly multiplexable assay, we have
achieved a sensitivity of 0.01% mutant/methylated allele fractions. Our
optimized assay has the ability to detect down to 16 pg (~4 genome
equivalents) of hypermethylated DNA spiked-in to 3.5 mL of plasma. 3) We
have utilized the MagSifter and immunocytochemistry combined with
automated image analysis and machine learning techniques (random forest,
transfer learning) for the enumeration and diagnosis/prognosis of NSCLC
derived CTCs in patient samples, which are well suited for therapy
selection and monitoring.
Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonLiquid Biopsies 2019Liquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-03-27 17:30:002019-03-27 18:30:00Europe/LondonNanodiagnostic Tool for Comprehensive Assessment of Cancer in BloodLiquid Biopsies 2019 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
